BRISBANE, Calif.--(BUSINESS WIRE)--July 5, 2006--Tercica, Inc. (Nasdaq:TRCA - News) announced today that on June 30, 2006, the U.S. District Court for the Northern District of California issued rulings on summary judgment and claim construction in Tercica's patent infringement litigation against defendants Insmed Incorporated, Celtrix Pharmaceuticals, Inc. and Insmed Therapeutic Proteins, Inc. In the case, Tercica has alleged that the defendants have infringed and are infringing three patents: U.S. Patent No. 6,331,414 (the 414; IGF-1 production process patent), U.S. Patent No. 5,187,151 (the 151; method of use patent) and U.S. Patent No. 5,258,287 (the 287; BP-3 production process patent).
